Ex vivo Treatment of Cytomegalovirus in Human Donor Lungs Using a Novel Chemokine-Based Immunotoxin

Transmission of latent human cytomegalovirus (HCMV) via organ transplantation with post-transplant viral reactivation is extremely prevalent and results in substantial adverse impact on outcomes. Therapies targeting the latent reservoir within the allograft to mitigate viral transmission would represent a major advance. Here, we delivered an immunotoxin (F49A-FTP) that targets and kills latent HCMV aiming at reducing the HCMV reservoir from donor lungs using ex-vivo lung perfusion (EVLP).

Source: The Journal of Heart and Lung Transplantation - October 25, 2021 Category: Transplant Surgery Authors: Rafaela V.P. Ribeiro, Terrance Ku, Aizhou Wang, Layla Pires, Victor H. Ferreira, Vinicius Michaelsen, Aadil Ali, Marcos Galasso, Sajad Moshkelgosha, Anajara Gazzalle, Mads G. Jeppesen, Mette M. Rosenkilde, Mingyao Liu, Lianne G. Singer, Deepali Kumar, Sha Source Type: research